

Boston Scientific Welcomes Publication of Analysis of Patients Monitored by the LATITUDE® Patient Management System

Patients experienced a 50 percent relative reduction in risk of death compared to in-clinic follow-up

NATICK, Mass., Dec. 7, 2010 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of an analysis from its ALTITUDE® Clinical Science program in the current issue of *Circulation* that showed patients followed by the LATITUDE® Patient Management system experienced a 50 percent relative reduction in the risk of death compared to patients followed in-clinic only. The analysis also showed that heart failure patients who transmitted weight and blood pressure data via the LATITUDE system experienced an additional 10 percent reduction in the risk of death compared to other CRT-D patients followed by the LATITUDE system.

Boston Scientific has enrolled more than 180,000 patients on the LATITUDE system since its introduction in 2006. The LATITUDE system enables physicians to conduct remote follow-up of implantable cardiac device patients to monitor specific device information and heart health status. The system can also detect clinical events between scheduled in-clinic visits and send relevant data directly to physicians.

The ALTITUDE program enhances physician understanding of device therapy, outcomes and disease progression in a real-world setting for device patients followed by the LATITUDE system.

"Patients remotely monitored by physicians may fare better due to earlier notification of events, resulting in diagnosis or therapy that can reduce subsequent risk," said Leslie Saxon, M.D., F.A.C.C., Chief, Cardiovascular Medicine at the Cardiovascular and Thoracic Institute, University of Southern California, and chairperson of the ALTITUDE physician panel. "Remote follow-up may also encourage patients to be more aware of their health status."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.

These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.

For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations

Boston Scientific
Corporation

David Knutson
651-260-8288 (mobile)
Media Relations
Boston Scientific
Corporation

Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific
Corporation

Sean Wirtjes
508-652-5305 (office)
Investor Relations
Boston Scientific
Corporation

SOURCE Boston Scientific Corporation

<https://news.bostonscientific.com/news-releases?item=59286>